The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.
Susan Halabi
Honoraria - Bayer; BN ImmunoTherapeutics
Research Funding - Sanofi
William Kevin Kelly
No relevant relationships to disclose
Haojin Zhou
No relevant relationships to disclose
Andrew J. Armstrong
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Dendreon; Janssen; Medivation; Sanofi
Honoraria - Dendreon; Pfizer; Sanofi
Research Funding - Active Biotech; Dendreon; Janssen; Medivation; Novartis; Pfizer; Sanofi
David Quinn
Consultant or Advisory Role - Algeta; Amgen; Astellas Pharma; AVEO; Bayer; Dendreon; Fresenius Biotech; Medivation; Novartis; Pfizer; Prometheus
Honoraria - Algeta; Amgen; Astellas Pharma; AVEO; Bayer; Dendreon; Fresenius Biotech; Medivation; Novartis; Pfizer; Prometheus
Research Funding - Millennium; Sanofi
Karim Fizazi
No relevant relationships to disclose
Nicole C Solomon
No relevant relationships to disclose
Ian Tannock
Research Funding - Sanofi
Daniel Peter Petrylak
Research Funding - Sanofi
Michael J. Morris
Consultant or Advisory Role - Janssen (U); Millennium
Research Funding - Bayer; Sanofi
Eric Jay Small
No relevant relationships to disclose